What Полисорб МП Treats: Main Uses and Benefits

The primary role of this enterosorbent is to offer symptomatic relief and supportive therapeutic benefit across clinical contexts characterized by acute or recurrent toxic and allergic burdens. The application of highly dispersed silicon dioxide-based sorbents is relevant for conditions driven by the presence of toxins or irritants in the gut.

Key Therapeutic Applications

This medicine is commonly used across conditions presenting with the sudden onset of acute diarrhea, nausea, and vomiting often associated with food poisoning or intestinal infections. It is applied in clinical settings marked by the temporary physiological imbalance, such as in cases of acute poisoning or the presence of significant endogenous metabolic waste during systemic illnesses. Furthermore, it is relevant in situations where symptoms cluster into patterns requiring supportive management, such as the digestive and skin manifestations of food allergies or atopic dermatitis, and is used in pediatric settings for hyperbilirubinemia (jaundice) in newborns.

Patient Comfort and Supportive Management

By addressing these disruptive symptom manifestations, the product supports the management of these episodes, contributing to improved comfort during periods of heightened symptoms and assisting with maintaining functional stability. This symptomatic assistance helps ease the overall symptom load and supports patients during difficult episodes by easing distress.

“This approach is relevant when supportive symptom management is appropriate, helping ease the overall symptom load during periods of acute discomfort.”

QuickFact Block

Eligibility and Contraindications for Полисорб МП

The eligibility for using Полисорб МП is generally broad, covering both adults and children, with specific dosages adjusted by age or weight. Official regulatory information confirms that the product can be used by pregnant women as well as breastfeeding mothers, and it is considered safe for these groups.

Furthermore, no dose adjustments or special safety concerns are noted for elderly patients or those with renal or hepatic impairment, making it eligible for use in these populations.

Use of Полисорб МП is formally contraindicated (must not be used) in individuals with certain acute gastrointestinal conditions. These restrictions include:

• Active bleeding stomach and duodenal ulcer
• Acute gastrointestinal haemorrhagic disease
• Intestinal atony (lack of normal muscle tone/movement)

Additionally, the product is contraindicated for any individual with known hypersensitivity or allergy to the active substance, silicon dioxide.

Interactions with other medicines and products

The interaction profile of Полисорб МП is defined by its function as a non-absorbed enterosorbent, which acts solely by physical binding within the gastrointestinal tract. Consequently, its documented interactions are primarily related to administration timing and the resulting effect on the absorption of other substances. Systemic interactions, such as those mediated by CYP enzymes or specific drug transporters, are not officially documented.

Interaction Outcome and Administration Constraint

The official regulatory information states that co-administration with other orally administered medicinal products may result in a documented reduction of their therapeutic effectiveness. This potential for reduced exposure applies non-specifically to all medicines taken by mouth, as no specific medicinal products are listed as formally contraindicated combinations. To manage this non-systemic interaction, the official labeling imposes a mandatory administration timing rule. The Полисорб МП suspension must be taken at least 1 hour before the intake of all other oral medicinal products or food. This strict procedural constraint governs the combined use of the enterosorbent with any other oral agent.

Specific Non-Drug Interaction

The label also notes a specific constraint related to the duration of use: long-term use (exceeding 14 days) may officially lead to the impaired absorption of vitamins and calcium. This is a documented interaction between the adsorbent and essential nutrients, which contributes to the product's overall official interaction structure. The profile is therefore constrained by timing requirements and the potential for nutrient binding, rather than by systemic drug-drug interactions.

The mechanism of action for Полисорб МП is based on physico-chemical adsorption strictly confined to the gastrointestinal lumen. The highly dispersed SiO2 surface acts as a non-selective adsorbent, forming stable, non-dissociating complexes with various exogenous toxins, pathogens, and endogenous metabolites. This process initiates a net negative flux of noxious substances from the body by physical isolation of the intestinal barrier from irritants, reducing localized mediator release. A key pathway effect is the interruption of enterohepatic recirculation; the adsorbent targets substances like excess bilirubin and cholesterol complexes, preventing their re-absorption into the systemic circulation. Additionally, the sequestration of biologically active amines, such as histamine and serotonin, limits their systemic entry, modulating excessive physiological signaling. As a strictly absorption-restricted agent with zero systemic distribution, the drug's physiological consequences are confined solely to luminal clearance, making it unable to influence toxic processes driven by substances already distributed in blood or tissues.

How to Use Полисорб МП: Official Administration Guidelines

The use of Полисорб МП, an enterosorbent containing Colloidal Silicon Dioxide, is described in instructions detailing the route, preparation, dosage, and timing of administration.

Preparation and Route

Administration is strictly by the oral route. The drug is supplied as a powder and must be converted into a fresh aqueous suspension immediately prior to each intake. The powder portion should be mixed with water, with volumes typically ranging from 50 to 100 mL per dose.

Dosing Schedule and Timing

The dosing protocol is weight-based. The average daily dose for adults is set at 0.1 to 0.2 grams per kilogram (g/kg) of body weight, with a cap at a maximum daily dose of 0.33 g/kg. This total daily amount is administered in 3 to 4 divided portions.

A key procedural constraint involves timing: the suspension must be consumed 1 hour before or 1 hour after the patient eats a meal or takes any other oral medication. This separation rule is a crucial step in the administration guidelines. Dosage for pediatric patients must also be calculated strictly based on the child's body weight. The duration of use is typically 3 to 5 days for acute regimens, extending up to 10 to 15 days for longer-term courses depending on the clinical course.

Research Evidence / Overview of Studies for Полисорб МП

Evidence for Use in Acute Diarrhea and Intestinal Infections

Research exploring the use of Polisorb MP (Silicium Dioxide Colloidal) in conditions associated with acute gastrointestinal distress, such as infectious diarrhea and food poisoning, has been conducted in the form of short-term Randomized Controlled Trials (RCTs) and comparative clinical studies. These studies were used in research exploring how symptoms change over time in both adults and children, including hospitalized patients.

Studies monitored how symptoms evolved in the observed populations, with some comparative clinical findings describing measurements related to the timing of symptom normalization and the duration of the diarrhea syndrome. Trials reported on the measurement of changes in the severity of associated intoxication symptoms within the acute short-term period of administration. Long-term outcomes following recovery are not well characterized, and evidence quality varies across studies, as some reports rely on research using similar silica-based enterosorbents rather than only Polisorb MP.

Evidence for Management of Allergic Manifestations

Research relevant to allergic burdens, specifically for conditions like food allergies or atopic dermatitis, primarily involves open-label, randomized, and comparative clinical studies focused on infants and preschool children. Researchers explored outcomes related to inflammatory or irritative states by tracking changes in the severity of skin manifestations and the resolution of accompanying gastrointestinal symptoms.

Findings describing observations of changes in symptoms were reported over the short-term 10-to-14-day observation period. Certainty remains low due to limitations such as the use of open-label designs in some studies. Furthermore, follow-up durations were limited, and data is insufficient to understand the utility of the sorbent in a long-term management strategy for these chronic conditions.

What Remains Uncertain in the Research Record

The current evidence highlights what is known and what is still uncertain about the sorbent's research base. The main limitations include the short duration of most studies, which means long-term outcomes are not well characterized. Research focusing on episodes where symptoms become more noticeable contributes to understanding symptom patterns, but the sample sizes were modest in many trials, limiting the generalizability of the findings. The research record shows that more independent, large-scale Randomized Controlled Trials (RCTs) across different indications are necessary to contribute to a deeper understanding of symptom patterns and their evolution in diverse patient groups.

Key Studies & References

1. Clinical Trials Database Entry for Enterosorbent Use in Acute Intoxication

Common questions about Полисорб МП (FAQ)

Q: Can Polisorb MP affect the absorption of vitamins or minerals?

Official labeling addresses concerns regarding nutrient binding, stating that prolonged use, defined as courses exceeding 14 days, is associated in the labeling with the potential for impaired absorption of certain essential nutrients. The specific nutrients mentioned in official documents are vitamins and calcium.

Q: How might Polisorb MP interact with other medicines I am taking?

Regulatory documents specify that due to its physical binding mechanism, concurrent intake with any other orally administered medicine may reduce the effectiveness of those medicines. The official labeling specifies that administration should be separated by at least one hour from the intake of any other oral medicinal product.

Q: How long can the prepared solution be kept before it must be consumed?

The administration guidelines require the suspension to be prepared fresh immediately before each dose. However, official storage conditions confirm that the prepared aqueous suspension is stable and may be stored for a maximum period of 48 hours, after which it is recommended to discard it.

Q: Is it mandatory to drink a lot of water when taking Polisorb MP?

Official guidelines define the volume of water required only for preparing the dose (typically 50 to 100 mL). The official administration documents define the required volume for preparation but do not specify the need for additional large volumes of water.

Q: Can I take Polisorb MP if I have kidney problems?

Official safety documents confirm that no dose adjustments or special safety concerns are noted for use in individuals with renal (kidney) or hepatic (liver) impairment. The safety profile is dictated by the fact that the product is not absorbed into the body.

Q: Does the composition of Polisorb MP include sugar or sweeteners?

The composition defined in official regulatory documentation states that the medicinal product consists solely of the active substance, colloidal silicon dioxide. No other ingredients, such as sugar or artificial sweeteners, are listed as components of the product.

Q: Should Polisorb MP be taken on an empty stomach?

The official constraint is defined as being consumed at least one hour before or one hour after a meal. This procedural timing is designed to ensure the product is administered away from food intake.

Q: Why do the instructions say to take it between meals?

The required timing (one hour before or after meals) is a regulatory constraint imposed to address the potential for the product to bind and reduce the absorption and effectiveness of other substances, including nutrients and oral medications.

Q: Can Polisorb MP cause calcium deficiency?

Long-term use (exceeding 14 days) is associated with the potential for reduced absorption of essential nutrients, including calcium. The official label includes information regarding the prophylactic intake of calcium during prolonged courses.

Q: Is Polisorb MP classified as a food supplement or a medicine?

The product is formally registered and classified as a medicinal product (лекарственный препарат) in the official State Register of Medicines, indicating its status as a pharmaceutical drug rather than a dietary supplement.

Q: Is there an expiration date for Polisorb MP after the package is opened?

The official shelf life for the dry powder is five years when stored in the unopened package. After opening the package, the product must be stored in a tightly closed container in a dry place to maintain this stability and efficacy.

Q: Does Polisorb MP have a taste or smell?

The active substance, colloidal silicon dioxide, is officially described in regulatory documents as an amorphous powder that is both odorless and tasteless.

Q: Is Polisorb MP sold without a prescription?

Yes, the official regulatory information specifies that the product is dispensed from pharmacies as a non-prescription medicinal product.

Q: What is known about the long-term consequences of taking Polisorb MP?

The research record indicates that clinical studies have primarily focused on short-term periods. Data regarding long-term outcomes following the product’s use, beyond a few weeks, are therefore considered limited.

Q: Is Polisorb MP used for treating allergies?

Yes, official regulatory documents list its use for certain allergic diseases among its designated indications.

Q: What is in the composition of Polisorb MP besides the active substance?

The official composition indicates that the medicinal product contains solely the active substance, colloidal silicon dioxide, with no other ingredients or excipients listed.

Q: Can Polisorb MP be taken for disease prevention?

Official indications include the use of the product for both treatment and prevention (prophylactic purposes) of certain conditions, such as gestosis.

Q: Is it true that Polisorb MP can remove 'bad' cholesterol?

The official mechanism of action is described as binding certain metabolic products, including excess cholesterol and lipid complexes, to interrupt their re-absorption and facilitate excretion from the body.

Q: Is Polisorb MP a Russian or foreign-made preparation?

The official manufacturer of the medicinal product, as stated in the regulatory documentation, is based in Russia.

Q: What is the maximum duration of the Polisorb MP course?

The duration of use is not fixed but varies by condition. While acute courses typically last 3 to 5 days, specific courses for chronic conditions, such as chronic renal failure, are defined in official documents as lasting up to 25 to 30 days.

Storage and Disposal of Полисорб МП

Official regulatory documents define specific storage and stability requirements for PoliSorb MP (colloidal silicon dioxide) to maintain its integrity.

Storage Conditions

The dry powder must be stored at a temperature not exceeding 25 C or 30 C, depending on regional regulatory labeling. Due to the powder's sensitivity to moisture, the container must be kept tightly closed and stored in a dry place. The product must also be stored out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material, especially the prepared suspension after 48 hours, must be disposed of according to local regulatory requirements and should not be discarded via household waste or wastewater.